VistaGen Therapeutics (NASDAQ:VTGN) Posts Earnings Results, Beats Estimates By $0.06 EPS

VistaGen Therapeutics (NASDAQ:VTGN) released its quarterly earnings results on Friday. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.06, FiscalAI reports. The business had revenue of $1.48 million during the quarter, compared to the consensus estimate of $0.50 million. VistaGen Therapeutics had a negative return on equity of 133.02% and a negative net margin of 5,487.01%.

VistaGen Therapeutics Trading Up 1.4%

Shares of VistaGen Therapeutics stock traded up $0.00 during trading hours on Friday, reaching $0.27. 799,470 shares of the company’s stock were exchanged, compared to its average volume of 2,197,639. VistaGen Therapeutics has a 52-week low of $0.20 and a 52-week high of $5.14. The company has a fifty day moving average of $0.38 and a 200-day moving average of $0.52. The firm has a market capitalization of $11.98 million, a price-to-earnings ratio of -0.15 and a beta of 0.41.

Institutional Trading of VistaGen Therapeutics

A number of hedge funds have recently added to or reduced their stakes in VTGN. Virtu Financial LLC acquired a new position in shares of VistaGen Therapeutics during the 4th quarter valued at about $25,000. Tudor Investment Corp ET AL purchased a new position in VistaGen Therapeutics during the fourth quarter worth approximately $50,000. Millennium Management LLC boosted its holdings in shares of VistaGen Therapeutics by 853.0% in the 4th quarter. Millennium Management LLC now owns 197,045 shares of the company’s stock valued at $130,000 after purchasing an additional 176,369 shares during the last quarter. Luminus Management LLC acquired a new position in shares of VistaGen Therapeutics in the 4th quarter valued at $232,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in VistaGen Therapeutics during the fourth quarter valued at about $68,000. 78.39% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, June 3rd. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average price target of $0.95.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.